FDA Cites Akorn’s Exhibit Banner At ASHP Clinical Conference
This article was originally published in The Pink Sheet Daily
Executive Summary
Booth promotion for Nembutal fails to disclose any risk information, Office of Prescription Drug Promotion says in the fifth letter issued this year.
You may also be interested in...
FDA's Decline In Promotion Enforcement Highlighted By Celator Booth Letter
FDA's Office of Prescription Drug Promotion issues only its third letter of 2016, although it hopes to cast wide net by targeting high-profile events like ASCO.
FDA Turns Off Otsuka’s Abilify Dimmer Switch Graphic
As lights go out on the franchise, FDA says pharmacology aid misleadingly suggests Abilify offers advantages over other treatments.
What Would US FDA Do If Supreme Court Eliminates Or Curtails Chevron Deference?
Lawyers say agency will have to bolster its administrative record as judges tackle complex policy and scientific issues previously left to FDA. Some cases, such as challenges to exclusivity decisions, may be reopened.